Lilly perseveres in a bad day for drug stocks — plus, Boeing's mixed deliveries

Stocks declined as rising oil prices and bond yields pressured the S&P 500 and Nasdaq, while investors awaited Thursday's PPI and Friday's CPI data ahead of next week's Fed meeting. Novartis plunged 11% after its Phase 3 Lp(a) cardiovascular trial failed to improve outcomes despite lowering Lp(a), dragging Amgen down about 9% and Eli Lilly 2%. Boeing delivered 51 aircraft in August, down from 57 a year earlier and 53 in July, although 737 Max deliveries improved to 41 and September rollouts are expected to approach 47 per month.

Analysis

The Lp(a) outcome failure is more damaging to the therapeutic class than to the individual sponsor: biomarker reduction without event reduction raises the required efficacy bar for AMGN's olpasiran and compresses the probability-adjusted value of its cardiovascular pipeline. The key differentiator is whether competing agents achieve materially deeper and more durable Lp(a) suppression, but until outcome data establish that distinction, AMGN should retain a higher clinical-risk discount. LLY's relative insulation reinforces its premium-growth profile, although its valuation leaves little room for obesity execution or reimbursement disappointments over the next 6-18 months.

AI infrastructure demand remains structurally intact, but NVDA's intraday reversal despite favorable compute-validation news suggests marginal buyers are increasingly constrained by rates and positioning rather than fundamentals. Over the next several days, inflation data matter more for semiconductor multiples than incremental model announcements: a higher-real-yield move can drive a 5-10% de-rating in crowded AI leaders even absent an earnings revision. This favors maintaining exposure through quality leaders but avoiding momentum adds before the macro catalyst.

BA is approaching a cleaner operational setup than its share price implies if monthly narrowbody output converts into customer deliveries without renewed quality or supply-chain disruption. The equity remains a leveraged proxy for airline cash flows, so sustained oil strength can cap near-term upside; however, cancellation risk should be assessed through order-book activity and deferrals rather than crude-price correlation alone. A credible delivery-rate outlook at the upcoming management appearance is the 1-3 month catalyst, while free-cash-flow normalization remains a 6-18 month debate.

Contrarian view: the healthcare selloff may be underestimating the possibility that this is target-class invalidation rather than a one-company execution issue, while the AI reaction may be overestimating the immediate revenue value of a single training deployment. The more actionable dispersion is within biotech risk-adjusted pipeline exposure and between BA's operational milestones and macro-driven sentiment.

Key Decisions for Investors

• Maintain an AMGN underweight versus LLY through the next 1-3 months; use a long LLY / short AMGN pair only if AMGN's post-event drawdown stabilizes, targeting a further 5-8% relative move. Cover if AMGN provides evidence of meaningfully superior Lp(a) lowering, durability, or a differentiated outcomes-trial design.
• Do not add to NVDA ahead of PPI/CPI. For existing long exposure, buy 1-2 month downside protection via NVDA put spreads or reduce gross if the 10-year real yield breaks higher; re-add only after inflation data and a sustained recovery in semiconductor breadth. The upside case is intact over 6-18 months, but near-term risk/reward is asymmetric after the rebound.
• Initiate a tactical BA position only following management confirmation that monthly 737 deliveries can sustain the targeted run-rate and that supplier constraints are not worsening. Use a 3-6 month call spread rather than outright stock; invalidate on a delivery-guidance reduction, renewed regulatory production limits, or evidence of meaningful customer deferrals.
• Favor GILD and ABBV as lower-beta large-cap biopharma exposure over binary cardiovascular-pipeline names during the next quarter. Reassess if obesity-drug pricing, Medicare coverage assumptions, or broader drug-pricing policy changes weaken the relative earnings visibility.